Company news

Palisade Bio, Inc. news in 2023

Palisade Bio, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108

December 27, 2023

Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook

November 9, 2023

Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer

September 10, 2023

Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules

September 10, 2023

Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules

September 6, 2023

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

September 5, 2023

Palisade Bio Reports Second Quarter 2023 Financial Results

August 10, 2023

Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

August 8, 2023

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

July 4, 2023

Palisade Bio Promotes J.D. Finley to Chief Executive Officer

May 31, 2023

Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts

May 23, 2023

Palisade Bio Reports First Quarter 2023 Financial Results

May 11, 2023

Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

May 10, 2023

Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148

April 5, 2023

Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148

April 4, 2023

Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

April 2, 2023

Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

March 22, 2023

Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent

February 28, 2023

Palisade Bio Promotes Robert McRae to Chief Operating Officer

February 7, 2023

Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million

January 9, 2023

Decks in 2023